ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Combining an Anti-LAG-3 Antibody With Nivolumab in Melanoma

Paolo A. Ascierto, MD
Published Online:6:46 PM, Wed September 13, 2017

Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses the initial efficacy findings for the anti-LAG-3 antibody BMS-986016 plus nivolumab (Opdivo) in patients with immunotherapy-relapsed/refractory melanoma.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.